Trials / Completed
CompletedNCT05521269
Dose Study of ANX1502 in Healthy Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX1502 in Normal Healthy Volunteer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Annexon, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ANX1502 (prodrug) and ANX1439 (active drug) in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANX1502 | ANX1502 is a prodrug of ANX1439. |
| DRUG | Placebo | Placebo comparator. |
Timeline
- Start date
- 2022-06-27
- Primary completion
- 2024-11-19
- Completion
- 2024-11-19
- First posted
- 2022-08-30
- Last updated
- 2024-12-27
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05521269. Inclusion in this directory is not an endorsement.